Published in Australas Med J on April 30, 2012
The CAPITA study of protein-conjugate pneumococcal vaccine and its implications for use in adults in developed countries. Hum Vaccin Immunother (2014) 0.75
23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet (2000) 4.23
Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis (2000) 4.01
Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (2008) 3.13
Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep (2010) 2.52
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med (2010) 2.30
Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine (2011) 2.03
The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis (2009) 2.02
Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis (2001) 1.70
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis (2008) 1.55
Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med (1997) 1.50
Immunological responses to pneumococcal vaccine in frail older people. Vaccine (2008) 1.36
Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis (2006) 1.17
Denmark14-230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol (2009) 1.15
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis (2008) 1.14
Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis (2009) 1.05
Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 0.99
Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis (2009) 0.93
Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS (2010) 0.92
Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int (2008) 0.90
Pneumococcal conjugate vaccine, polysaccharide vaccine, or both for adults? We're not there yet. Clin Infect Dis (2009) 0.83
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis (2003) 5.21
Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) (2003) 3.66
Inappropriate treatment of catheter-associated asymptomatic bacteriuria in a tertiary care hospital. Clin Infect Dis (2009) 3.10
Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis (2005) 2.68
A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) (2003) 2.51
Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis (2003) 2.50
Rickettsia sibirica infection in members of scientific expeditions to northern Asia. Lancet (2003) 2.20
Long-term survival following pneumococcal pneumonia. Clin Infect Dis (2013) 2.15
Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol (2006) 2.05
Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis (2012) 1.82
Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med (2002) 1.81
Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis (2009) 1.70
Secondary syphilitic lesions. Clin Microbiol Rev (2005) 1.64
Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect (2011) 1.57
Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (2006) 1.57
Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation (2012) 1.52
Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis (2010) 1.41
Pneumococcal vaccine--direct and indirect ("herd") effects. N Engl J Med (2006) 1.32
Acute pneumonia and the cardiovascular system. Lancet (2013) 1.25
Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm (2007) 1.18
Impact of an assay that enables rapid determination of Staphylococcus species and their drug susceptibility on the treatment of patients with positive blood culture results. Infect Control Hosp Epidemiol (2010) 1.17
Hyperglycemia in diabetics and non-diabetics: effect on the risk for and severity of pneumococcal pneumonia. J Infect (2009) 1.15
Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) (2009) 1.14
Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med (2003) 1.06
A 57-year-old man with a fluid-containing lung cavity: infection of an emphysematous bulla with methicillin-resistant Staphylococcus aureus. Chest (2006) 1.05
Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis (2003) 1.04
The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. Medicine (Baltimore) (2010) 1.03
Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect (2008) 1.02
The obesity paradox in community-acquired bacterial pneumonia. Int J Infect Dis (2010) 0.95
Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother (2012) 0.95
Surgical versus nonsurgical treatment of empyema thoracis: an outcomes analysis. Am J Med Sci (2003) 0.93
Interaction between human polymorphonuclear leukocytes and Streptococcus milleri group bacteria. J Infect Dis (2001) 0.93
In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother (2004) 0.92
Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy (2007) 0.91
Community-Acquired Pneumonia Requiring Hospitalization. N Engl J Med (2015) 0.91
An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease. Gastroenterol Clin North Am (2006) 0.91
The incidence of necrotizing changes in adults with pneumococcal pneumonia. Clin Infect Dis (2011) 0.90
Neurosyphilis: diagnosis and response to treatment. Clin Infect Dis (2008) 0.88
A nosocomial outbreak of norovirus infection masquerading as clostridium difficile infection. Clin Infect Dis (2009) 0.87
Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin. Scand J Infect Dis (2012) 0.87
Genome analysis of a highly virulent serotype 1 strain of Streptococcus pneumoniae from West Africa. PLoS One (2012) 0.87
Epidemic Clostridium difficile. N Engl J Med (2006) 0.87
It's not that simple. Clin Infect Dis (2012) 0.86
The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci (2013) 0.86
IRIS iQ200 workstation as a screen for performing urine culture. Diagn Microbiol Infect Dis (2012) 0.85
Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by clostridium difficile. Clin Infect Dis (2002) 0.82
Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent. Future Microbiol (2007) 0.81
Clinical Diagnosis, Viral PCR, and Antibiotic Utilization in Community-Acquired Pneumonia. Am J Ther (2016) 0.80
Community-acquired pneumonia. N Engl J Med (2015) 0.80
Pneumococcal pyomyositis: report of 2 cases and review of the literature. Clin Infect Dis (2012) 0.79
The usefulness of sputum gram stain and culture. Arch Intern Med (2005) 0.79
Severe pulmonary involvement in a case attributed to domestically acquired Seoul hantavirus in the United States. Clin Infect Dis (2011) 0.79
The association between Staphylococcus aureus bacteremia and acute myocardial infarction. Scand J Infect Dis (2009) 0.79
Device-related infective endocarditis, with special consideration of implanted intravascular and cardiac devices in a predominantly male population. Scand J Infect Dis (2012) 0.79
Undisclosed conflicts of interest. Ann Intern Med (2006) 0.79
Clinical significance of Staphylococcus aureus bacteriuria at a tertiary care hospital. Scand J Infect Dis (2013) 0.78
Preventing myocardial infarction with vaccination: myths and realities. JAMA (2010) 0.78
The long-term outcome of treatment of Clostridium difficile colitis. Clin Infect Dis (2007) 0.78
Antibiotic stewardship and Clostridium difficile-associated disease. Infect Control Hosp Epidemiol (2008) 0.78
The lack of therapeutic benefit of adding hydroxyurea to highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr (2002) 0.77
Computerized tomography (CT)-guided aspiration of abscesses: outcome of therapy at a tertiary care hospital. J Infect (2006) 0.77
Pneumococcal serotypes and virulence. J Infect Dis (2006) 0.75
Diagnosis of Clostridium difficile infection. Clin Infect Dis (2012) 0.75
V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons. Clin Vaccine Immunol (2011) 0.75
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 0.75
Ulceronodular syphilis (lues maligna praecox) in a person newly diagnosed with HIV infection. BMJ Case Rep (2011) 0.75
Benefits and costs of rapid drug susceptibility in Staphylococcus aureus bacteremia. Clin Infect Dis (2011) 0.75
Anemia and infection. Clin Infect Dis (2004) 0.75
The naming of strep, with apologies to T. S. Eliot. Clin Infect Dis (2009) 0.75
Dichotomy between content and interpretation. Clin Infect Dis (2009) 0.75
Diagnosis still in question. N Engl J Med (2002) 0.75
Bacteraemia from an unrecognized source (occult bacteraemia) occurring during Clostridium difficile infection. Scand J Infect Dis (2011) 0.75
Photo quiz. To scan or not to scan? Clin Infect Dis (2013) 0.75
Clostridium difficile lacks detectable superantigen activity. FEMS Immunol Med Microbiol (2006) 0.75